Corona Remedies reported a strong Q2 FY27 with revenue rising 22.2% YoY to INR 441 crore, driven by a 22.9% jump in its domestic business. Despite higher depreciation costs impacting PAT growth at 15.3%, the company is aggressively expanding into niche therapies like IVF and nephrology. With a focus on outperforming the Indian Pharmaceutical Market by 1.5x, the company remains a key player to watch in the specialty segments.
Corona Remedies Q2 FY27: Revenue at INR 441 Crore, PAT at INR 60 Crore
Reader Takeaway: Strong double-digit revenue growth outpaces market averages, while higher depreciation on new assets pressures near-term profit margins.
What just happened
Corona Remedies has announced its financial results for the second quarter of FY27, showing robust growth across its core business metrics. The company reported a revenue of INR 441 crore, marking a 22.2% increase compared to INR 361 crore in Q2 FY26. EBITDA grew by 22.3% to reach INR 96 crore, while Profit After Tax (PAT) stood at INR 60 crore, a 15.3% rise from the previous year. The domestic business remains the primary engine, contributing 97% of total revenue with a 22.9% growth rate for the quarter.
Why this matters
The company’s performance highlights its ability to significantly outperform the broader Indian Pharmaceutical Market. Its chronic segment recorded a 29% growth, nearly doubling the 14.9% growth seen in the corresponding market segment. This validates the firm's strategic focus on specialized therapies. Furthermore, management remains optimistic about maintaining a growth rate of 1.5x the Indian Pharmaceutical Market rate in the coming quarters.
Strategic Developments
Corona Remedies is aggressively entering high-growth therapeutic areas, including infertility (IVF), nephrology, gastroenterology, and rheumatology. Management has also confirmed it is actively scouting for inorganic growth opportunities, evaluating potential brand and company acquisitions. On the international front, the firm expects revenue of INR 60-65 crore this year, maintaining a niche focus on the hormone market.
Risks to watch
The primary concern for investors is the bottom-line pressure resulting from increased depreciation and amortization costs linked to newly commissioned facilities and brand acquisitions. Additionally, the integration of the recently acquired Wokadine brand is moving at a slower pace than initially projected by management, though the long-term outlook for the brand remains positive.
Context metrics
The company’s exposure to the National List of Essential Medicines (NLEM) is relatively low at 7.5%, shielding it from major price control volatility. The EBITDA margin remained steady at 21.7%.